NASDAQ:ONCY Oncolytics Biotech Q4 2025 Earnings Report $0.76 -0.04 (-4.43%) As of 03:03 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Oncolytics Biotech EPS ResultsActual EPS-$0.08Consensus EPS -$0.06Beat/MissMissed by -$0.02One Year Ago EPSN/AOncolytics Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AOncolytics Biotech Announcement DetailsQuarterQ4 2025Date3/31/2026TimeBefore Market OpensConference Call DateMonday, March 30, 2026Conference Call Time7:00AM ETUpcoming EarningsOncolytics Biotech's Q2 2026 earnings is estimated for Friday, July 31, 2026, based on past reporting schedulesConference Call ResourcesAnnual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(10-K) Oncolytics Biotech Earnings HeadlinesOncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal CancerJuly 20, 2026 | globenewswire.comONCY: Seeking Registration Pathway for Part B of REO 033 TrialJuly 16, 2026 | finance.yahoo.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.July 29 at 1:00 AM | Porter & Company (Ad)Oncolytics Biotech Announces Rapid REO 033 Site Activation and FDA Meeting on Registrational Pathway for Pelareorep in Metastatic Colorectal CancerJuly 13, 2026 | quiverquant.comQOncolytics Biotech® Reports FDA Regulatory Milestone and Strong Clinical Progress in Randomized RAS-Mutant MSS Colorectal Cancer TrialJuly 13, 2026 | globenewswire.comOncolytics Biotech Secures New Pelareorep Manufacturing PatentJune 16, 2026 | tipranks.comSee More Oncolytics Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Oncolytics Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Oncolytics Biotech and other key companies, straight to your email. Email Address About Oncolytics BiotechOncolytics Biotech (NASDAQ:ONCY) (NASDAQ: ONCY) is a clinical-stage biotechnology company focused on the development of novel oncolytic viral therapies for the treatment of cancer. The company’s lead investigational agent, pelareorep (Reolysin), is a proprietary formulation of reovirus engineered to selectively infect and destroy tumor cells while stimulating a systemic antitumor immune response. Oncolytics leverages the natural biology of the virus to enhance the activity of standard‐of‐care treatments and immune checkpoint inhibitors. Pelareorep has progressed into multiple advanced clinical trials, with combination studies conducted in metastatic breast cancer, non‐small cell lung cancer and head and neck cancers. Collaborations with academic centers and pharmaceutical partners support ongoing research into optimal dosing regimens, novel combination strategies and biomarker identification. The company also maintains an early-stage pipeline of additional viral candidates aimed at broadening its platform of immune‐activating cancer therapies. Headquartered in Calgary, Alberta, with a research and development facility in Houston, Texas, Oncolytics sustains a presence in major North American life science hubs. The company’s infrastructure supports integrated translational research, process development and global clinical trial management, with a focus on advancing regulatory filings and securing strategic partnerships to accelerate commercialization. Under the leadership of President and Chief Executive Officer Brad Thompson, Oncolytics’ management team brings extensive experience in oncology drug development, virology and biopharmaceutical operations. The company remains committed to advancing its viral immunotherapy platform through rigorous clinical investigation and collaborative programs designed to address unmet needs in oncology.View Oncolytics Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Why Bloom Energy May Be the Most Important AI Infrastructure StockCarrier Earnings Could Send the Stock to a New All-Time High3 Refiners Benefiting From Oil Volatility and Tight Fuel SupplyWelltower at 52-Week Highs—But Analysts Believe There's More to ComeThese 3 Stocks Have Soared in 2026—Can They Keep Climbing?UPS Just Gave Investors a Second Chance to BuyHasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story Upcoming Earnings Ferrari (7/30/2026)Air Products and Chemicals (7/30/2026)ArcelorMittal (7/30/2026)Vale (7/30/2026)Mastercard (7/30/2026)Apple (7/30/2026)ASE Technology (7/30/2026)Monolithic Power Systems (7/30/2026)CRH (7/30/2026)Quanta Services (7/30/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
